Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for RUA Life Sciences's Debt-to-EBITDA or its related term are showing as below:
FRA:AOHA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.32 Med: -0.24 Max: 93
Current: 93
During the past 13 years, the highest Debt-to-EBITDA Ratio of RUA Life Sciences was 93.00. The lowest was -0.32. And the median was -0.24.
FRA:AOHA's Debt-to-EBITDA is ranked worse than 100% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs FRA:AOHA: 93.00
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
RUA Life Sciences Debt-to-EBITDA Related Terms
RUA Life Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AOHA vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, RUA Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
RUA Life Sciences (FRA:AOHA) has a Debt-to-EBITDA of 46.88 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on RUA Life Sciences. According to the industry distribution chart, RUA Life Sciences ranks #471 out of 471 companies in the Medical Devices & Instruments industry.
Is RUA Life Sciences' Debt-to-EBITDA too high?
RUA Life Sciences' current Debt-to-EBITDA is 46.88. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. RUA Life Sciences' value of 46.88 is 2776.1% above this industry median. Based on the distribution chart, RUA Life Sciences ranks #471 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, RUA Life Sciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #471 out of 471 companies for Debt-to-EBITDA. This places RUA Life Sciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. RUA Life Sciences' value of 46.88 is 2776.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RUA Life Sciences's current Debt-to-EBITDA of 46.88 is 2776.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on RUA Life Sciences. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current Debt-to-EBITDA is 46.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €0.28 — trading 84% above its estimated fair value. The current Debt-to-EBITDA is 46.88 and 2776.1% above the Medical Devices & Instruments industry median of 1.63. RUA Life Sciences' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current Debt-to-EBITDA is 46.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.28 is trading 84% above its estimated GF Value™ of €0.15.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
Debt-to-EBITDA: 46.88
GF Value™: €0.15 vs. price of €0.28 (84% above fair value)
Industry Position: 2776.1% above the Medical Devices & Instruments median (#471 of 471)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
46GF Score
Get the complete analysis for FRA:AOHA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
